1,159,840 Shares in DENTSPLY SIRONA Inc. $XRAY Bought by Ninety One UK Ltd

Key Points

• Ninety One UK Ltd has acquired 1,159,840 shares of DENTSPLY SIRONA Inc., valued at approximately $18.4 million, representing about 0.58% ownership in the company.
• DENTSPLY SIRONA reported a quarterly EPS of $0.52, surpassing analysts' expectations, but its revenue declined by 4.9% compared to the previous year.
• The company declared a quarterly dividend of $0.16, scheduled for payment on October 10th, 2023, yielding 4.9% annually.

Ninety One UK Ltd purchased a new position in shares of DENTSPLY SIRONA Inc. (NASDAQ:XRAY - Free Report) during the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor purchased 1,159,840 shares of the medical instruments supplier's stock, valued at approximately $18,418,000. Ninety One UK Ltd owned approximately 0.58% of DENTSPLY SIRONA at the end of the most recent quarter.

A number of other hedge funds and other institutional investors also recently modified their holdings of XRAY. Mirae Asset Global Investments Co. Ltd. bought a new stake in shares of DENTSPLY SIRONA in the 1st quarter valued at about $25,000. Brooklyn Investment Group acquired a new position in DENTSPLY SIRONA during the first quarter worth approximately $26,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. acquired a new position in DENTSPLY SIRONA during the first quarter worth approximately $26,000. Caitong International Asset Management Co. Ltd raised its stake in DENTSPLY SIRONA by 8,003.6% in the first quarter. Caitong International Asset Management Co. Ltd now owns 2,269 shares of the medical instruments supplier's stock valued at $34,000 after buying an additional 2,241 shares during the period. Finally, MassMutual Private Wealth & Trust FSB lifted its position in shares of DENTSPLY SIRONA by 160.2% in the second quarter. MassMutual Private Wealth & Trust FSB now owns 2,805 shares of the medical instruments supplier's stock valued at $45,000 after buying an additional 1,727 shares during the last quarter. Institutional investors own 95.70% of the company's stock.

Analyst Ratings Changes

Several brokerages have recently commented on XRAY. Needham & Company LLC reiterated a "hold" rating on shares of DENTSPLY SIRONA in a research note on Friday, September 26th. Wells Fargo & Company cut their price target on DENTSPLY SIRONA from $16.00 to $15.00 and set an "equal weight" rating for the company in a report on Friday, August 8th. UBS Group reduced their price objective on shares of DENTSPLY SIRONA from $25.00 to $24.00 and set a "buy" rating for the company in a research report on Friday, August 8th. Wall Street Zen raised shares of DENTSPLY SIRONA from a "hold" rating to a "buy" rating in a research report on Friday, September 26th. Finally, Barrington Research cut their target price on shares of DENTSPLY SIRONA from $21.00 to $18.00 and set an "outperform" rating for the company in a research note on Friday, August 8th. Two equities research analysts have rated the stock with a Buy rating and eleven have given a Hold rating to the company. According to MarketBeat, the stock currently has an average rating of "Hold" and a consensus target price of $18.64.

DENTSPLY SIRONA Stock Up 2.0%

XRAY opened at $12.95 on Thursday. The stock has a fifty day moving average of $13.92 and a 200-day moving average of $14.76. The company has a market capitalization of $2.58 billion, a P/E ratio of -2.73, a P/E/G ratio of 0.79 and a beta of 0.96. DENTSPLY SIRONA Inc. has a fifty-two week low of $12.14 and a fifty-two week high of $25.76. The company has a debt-to-equity ratio of 1.13, a quick ratio of 1.11 and a current ratio of 1.69.

DENTSPLY SIRONA (NASDAQ:XRAY - Get Free Report) last released its quarterly earnings results on Thursday, August 7th. The medical instruments supplier reported $0.52 EPS for the quarter, topping analysts' consensus estimates of $0.50 by $0.02. DENTSPLY SIRONA had a negative net margin of 25.85% and a positive return on equity of 16.33%. The business had revenue of $936.00 million for the quarter, compared to analyst estimates of $929.67 million. During the same period last year, the firm earned $0.49 earnings per share. DENTSPLY SIRONA's revenue for the quarter was down 4.9% compared to the same quarter last year. DENTSPLY SIRONA has set its FY 2025 guidance at 1.800-2.000 EPS. On average, equities analysts expect that DENTSPLY SIRONA Inc. will post 1.84 EPS for the current year.

DENTSPLY SIRONA Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Friday, October 10th. Shareholders of record on Friday, September 26th will be issued a $0.16 dividend. The ex-dividend date of this dividend is Friday, September 26th. This represents a $0.64 annualized dividend and a yield of 4.9%. DENTSPLY SIRONA's payout ratio is currently -13.50%.

DENTSPLY SIRONA Company Profile

DENTSPLY SIRONA Inc manufactures and sells various dental products and technologies worldwide. It operates in four segments: Connected Technology Solutions, Essential Dental Solutions, Orthodontic and Implant Solutions, and Wellspect Healthcare. The company offers dental equipment comprising imaging equipment, motorized dental handpieces, treatment centers, other instruments, amalgamators, mixing machines, and porcelain furnaces; and dental CAD/CAM technologies to support dental restorations, such as intraoral scanners, 3-D printers, mills, other software and services, and a full-chairside economical restoration of esthetic ceramic dentistry, as well as DS Core, its cloud-based platform.

Want to see what other hedge funds are holding XRAY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for DENTSPLY SIRONA Inc. (NASDAQ:XRAY - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.